



Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

June 1, 2017

BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 1, 2017-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June:

- **Jefferies 2017 Global Healthcare Conference**
Presentation: Friday, June 9, 2017 at 9:30 a.m. Eastern Time
The Grand Hyatt New York Hotel, New York, NY
- **JMP Securities 2017 Life Sciences Conference**
Panel Discussion: "Innovations in Ophthalmology"
Tuesday, June 20, 2017 at 4:00 p.m. Eastern Time
The St. Regis New York Hotel, New York, NY

A live audio webcast of the presentation at the Jefferies Healthcare Conference can be accessed through the Investors section of the Company's website at investors.ocutx.com. A replay of the webcast will be available on the Company's website for two weeks following the live presentation.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. The FDA has accepted the Company's NDA resubmission for DEXTENZA for the treatment of ocular pain following ophthalmic surgery and has established a PDUFA target action date of July 19, 2017. If approved, the Company intends to submit a supplement to its NDA for ocular inflammation. OTX-TP (travoprost insert) is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170601005160/en/>

Source: Ocular Therapeutix, Inc.

Media

Medical Dynamics
Sandra Correa, 646-599-8637
Business & Media Group Director
scorrea@rxmedyn.com

or

Investors

Burns McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
sklass@burnsmc.com

or

Ocular Therapeutix

Scott Corning
Vice President of Marketing & Commercial Operations
scorning@ocutx.com